Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06941870 · ClinicalTrials.gov registry record · Phase 4
Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy
A Phase 4 study of Factor VIII Deficiency, sponsored by Sanofi.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 35
- Enrollment target
- 13
- Study locations
NCT06941870: Recruiting Phase 4 study of Factor VIII Deficiency, sponsored by Sanofi.
NCT06941870 is a Phase 4 study of Factor VIII Deficiency that is actively recruiting participants, run by Sanofi. The registered enrollment target is 35 participants. The trial reports 13 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06941870, a Phase 4 study of Factor VIII Deficiency, is actively recruiting participants, sponsored by Sanofi.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 35 participants
- Enrollment target
- 13
- Study locations
Study Summary
The objective of the study is to assess the improvement of synovial hypertrophy during the 12 months of efanesoctocog alfa prophylaxis once per week (QW) in joints with existing evidence of synovial hypertrophy in participants with hemophilia A. The study duration for each participant is approximately 12 months.
Conditions Studied
Interventions
- DRUG Efanesoctocog alfa
Study Locations (13)
Other
- Investigational Site Number : 3920002 - Hiroshima
- Investigational Site Number : 3920001 - Saitama
- Investigational Site Number : 3920004 - Tokyo
- Investigational Site Number : 1580003 - Kaohsiung City
- Investigational Site Number : 1580001 - Taichung
- Investigational Site Number : 1580002 - Taipei
Ontario
- Investigational Site Number : 1240003 - Hamilton
- Investigational Site Number : 1240004 - Hamilton
California
- Orthopedic Institute for Children- Site Number : 8400009 - Los Angeles
Indiana
- Innovative Hematology, Inc.- Site Number : 8400006 - Indianapolis
Iowa
- University of Iowa- Site Number : 8400004 - Iowa City
Ohio
- Ohio State University Hospital East- Site Number : 8400001 - Columbus
Kanagawa
- Investigational Site Number : 3920003 - Kawasaki
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2025-09-23 |
| Est. Completion | 2027-10-25 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06941870
The ClinicalTrials.gov registry entry for NCT06941870 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Factor VIII Deficiency appearing as the primary indexed condition, and to 1 intervention - of which Efanesoctocog alfa is the first listed.
NCT06941870 reports 13 study locations spanning 7 distinct geographic areas - top geographies include Other, Ontario, California.
Frequently Asked Questions
What is clinical trial NCT06941870 about?
NCT06941870 is a clinical study titled "Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy". The objective of the study is to assess the improvement of synovial hypertrophy during the 12 months of efanesoctocog alfa prophylaxis once per week (QW) in joints with existing evidence of synovial hypertrophy in participants with hemophilia A. The study duration for each participant is approximat...
What is the current status of trial NCT06941870?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 35 participants. The study started on 2025-09-23. Estimated completion is 2027-10-25.
What conditions does trial NCT06941870 study?
This clinical trial studies the following conditions: Factor VIII Deficiency.
What interventions are being tested in trial NCT06941870?
The interventions under investigation include: Efanesoctocog alfa (DRUG).
Who is sponsoring clinical trial NCT06941870?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06941870 being conducted?
This trial has 13 study locations across California, Indiana, Iowa, Ohio, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.